---
figid: PMC11783702__13023_2024_3413_Fig3_HTML
figtitle: RAS/MAPK signalling pathway, extracted from article by Seebacher et al
organisms:
- NA
organisms_ner:
- Danio rerio
pmcid: PMC11783702
filename: 13023_2024_3413_Fig3_HTML.jpg
figlink: /pmc/articles/PMC11783702/figure/F3/
number: F3
caption: Diagram of the RAS/MAPK signalling pathway, extracted from article by Seebacher
  et al. 2019 (Fig. 5) [31]. RAS activates both the CRAF and the BRAF pathways. Shown
  BRAF and MEK inhibitors are FDA approved for the treatment of cancer
papertitle: 'Diagnosis and management of superficial arteriovenous malformations:
  French healthcare network’s recommendations'
reftext: Olivia Boccara, et al. Orphanet J Rare Dis. 2025;20(NA).
year: '2025'
doi: 10.1186/s13023-024-03413-5
journal_title: Orphanet Journal of Rare Diseases
journal_nlm_ta: Orphanet J Rare Dis
publisher_name: BMC
keywords: Superficial arteriovenous malformations | Differential diagnosis | Assessment
  of disease extent | Medical and therapeutic management | Psychosocial care | French
  Healthcare organization
automl_pathway: 0.9494042
figid_alias: PMC11783702__F3
figtype: Figure
redirect_from: /figures/PMC11783702__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC11783702__13023_2024_3413_Fig3_HTML.html
  '@type': Dataset
  description: Diagram of the RAS/MAPK signalling pathway, extracted from article
    by Seebacher et al. 2019 (Fig. 5) [31]. RAS activates both the CRAF and the BRAF
    pathways. Shown BRAF and MEK inhibitors are FDA approved for the treatment of
    cancer
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - kita
  - ngfra
  - pak2a
  - itpka
  - raf1a
  - nras
  - braf
  - si:dkey-222f8.3
  - Tyrosine
  - COBIMETINIB
  - TRAMETINIB
  - MEK
  - SORAFENIB
  - VEMURAFENIB
  - DABRAFENIB
  - REGORAFENIB
---
